Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04558567 · ClinicalTrials.gov registry record · Phase 4
Vogelxo(R) ABPM Study in Hypogandal Men
A Phase 4 study of Hypogonadism, Male, sponsored by Upsher-Smith Laboratories.
- Completed
- Registry status
- Phase 4
- Development phase
- 122
- Enrollment target
- 7
- Study locations
NCT04558567 is a Phase 4 study of Hypogonadism, Male that has completed, run by Upsher-Smith Laboratories. The registered enrollment target is 122 participants, above the 102-participant average among 12 other Hypogonadism, Male trials with a reported enrollment target (20% higher). The trial reports 7 study locations across 6 states.
The verdict
NCT04558567, a Phase 4 study of Hypogonadism, Male, has completed, sponsored by Upsher-Smith Laboratories.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 122 participants
- Enrollment target
- 7
- Study locations
Study Summary
A Phase 4 ABPM study in Hypogonadal Men
Conditions Studied
Interventions
- DRUG Vogelxo
Study Locations (7)
Texas
- Upsher-Smith Clinical Trials Site #5 - San Antonio
- Upsher-Smith Clinical Trials Site #8 - San Antonio
Alabama
- Upsher-Smith Clinical Trial Site #6 - Birmingham
California
- Upsher-Smith Clinical Trial Site #2 - Anaheim
Florida
- Upsher-Smith Clinical Trial Site #1 - Miami
New York
- Upsher-Smith Clinical Trials Site #7 - Garden City
South Carolina
- Upsher-Smith Clinical Trials Site #4 - North Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2020-08-28 |
| Est. Completion | 2024-01-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04558567
The ClinicalTrials.gov registry entry for NCT04558567 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 102-participant average among 12 other Hypogonadism, Male trials with a reported enrollment target (20% higher). The listed sponsor is Upsher-Smith Laboratories, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypogonadism, Male appearing as the primary indexed condition, and to 1 intervention - of which Vogelxo is the first listed.
NCT04558567 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Texas, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT04558567 about?
NCT04558567 is a clinical study titled "Vogelxo(R) ABPM Study in Hypogandal Men". A Phase 4 ABPM study in Hypogonadal Men
What is the current status of trial NCT04558567?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 122 participants. The study started on 2020-08-28. Estimated completion is 2024-01-11.
What conditions does trial NCT04558567 study?
This clinical trial studies the following conditions: Hypogonadism, Male.
What interventions are being tested in trial NCT04558567?
The interventions under investigation include: Vogelxo (DRUG).
Who is sponsoring clinical trial NCT04558567?
This trial is sponsored by Upsher-Smith Laboratories, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04558567 being conducted?
This trial has 7 study locations across Alabama, California, Florida, New York, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypogonadism, Male
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Comparison of Side Effects in Hypogonadal Men Treated With Natesto Versus Testosterone Injections
COMPLETED · Phase 4
-
Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism
RECRUITING · Phase 2
-
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
RECRUITING · Phase 2
-
Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone
RECRUITING · Phase 2
-
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
RECRUITING · Phase 3
-
Testosterone Treatment in Men with Chronic Kidney Disease
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.